🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Very excited to join discussion 🎙on “Educating the #NextGen #Onc Leaders” 🧑‍🎓👨‍🎓as a panelist with FDA Oncology! Thank you 🙏🏻PJ Vellanki Jennifer Gao AACR #AACR22 for the opportunity! Come join the discussion tomorrow 10.15 am CST! #MedEd Mayo Clinic Hematology-Oncology Fellowship Hem-Onc Fellows Network OncoAlert

🚨LIVE NOW AACR #AACR22 #AcceleratedApproval FDA Oncology session moderated by Gautam Mehta, MD & looking forward to talks by Diana Bradford Sara Whitlock RET Renegades & Dr. Wirth cc Tatiana Prowell, MD Jennifer Gao

ICYMI: The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint, by #FDAOncology's Nicholas Richardson, Yvette Kasamon, Nicole Gormley and Rick Pazdur. #FDAODAC #PI3Kinhibitors #lymphoma #leukemia sciencedirect.com/science/articl…

WHAT A FINISH! In one of the greatest races in Boston Marathon history in the women's elite field, Olympic champion Peres Jepchirchir takes the win on Boylston Street. #Boston126

Great opportunity to discuss the use of #acceleratedapproval in #PrecisionMedicine. Learn more in the video below. #AACR2022 #cancer

Finding our place as #PalliativeCare specialists can be hard, but our words matter. Especially when we want people to listen to us #hapc #MedTwitter Journal of Pain and Symptom Management (JPSM) Johns Hopkins Medicine sciencedirect.com/science/articl…

Patients w/ brain tumors face barriers to enrollment in #clinicaltrials. Learn more + approaches to minimizing them in this paper by Drs. Eudocia Lee, Ross Camidge & Gautam Mehta, MD. 🧠 fal.cn/3oT95 #ASCOEdBook #CNStumors #btsm Friends of Cancer Research

Register for a free SSO webinar, taking place on June 23, to learn from FDA Oncology faculty about regulatory perspectives on cell and gene based #CancerTherapies. This webinar is the first in a two part series. Save your seat at ow.ly/Sekx50Jn5LL. Genevieve Boland, MD, PhD Gautam Mehta, MD

No better way to restart conference travel than a run on Chicago's Lakefront Trail! #ASCO22 #LetsGo!

Our FDA Oncology approval summary for belzutifan, a first-in-class HIF inhibitor which is the first drug approved for early treatment of von Hippel-Lindau disease-associated tumors Jaleh Fallah Gautam Mehta, MD Laleh Amiri-Kordestani, MD Julia Beaver pubmed.ncbi.nlm.nih.gov/35727604/

FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with unresectable or metastatic non-small cell lung cancer whose tumors have activating HER2 (ERBB2) mutations. #lcsm fda.gov/drugs/resource…

If you get on the freeway you gotta have a plan to get off #acceleratedapproval #oncology

💥 Just published today 👉🏼Accelerated approvals hit the target in precision oncology Nature Medicine #PrecisionMedicine U.S. FDA FDA Oncology nature.com/articles/s4159…

About a quarter of all #cancer #acceleratedapprovals have been granted for #PrecisionMedicines for solid tumors. Read about the program's unique challenges in this analysis with Vivek Subbiah, MD #LoriWirth Razelle Kurzrock, MD Harpreet Singh, MD Julia Beaver and Rick Pazdur

Accelerated approvals hit the target in precision oncology. Correspondence from Vivek Subbiah, MD, Gautam U. Mehta and colleagues MD Anderson Cancer Center U.S. FDA nature.com/articles/s4159…

FDA's Accelerated Approval is 30 years old this year. The first #AcceleratedApproval in oncology was granted on October 4, 1995, to bicalutamide in combination with an LHRH analogue for advanced #prostatecancer. Learn more with #OCEProjectConfirm 👇 fda.gov/about-fda/onco…

Really impactful piece in Journal of Clinical Oncology by a friend who understands #cancer from both the patient's and clinician's perspective. #LCSM #oncology #chasingmilestones ascopubs.org/doi/full/10.12…

#FDAOncology Drs. Martha Donoghue, Gautam Mehta Gautam Mehta, MD and Nicole Drezner at the Cancer Moonshot Brain Cancers Forum on Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma, held at the Eisenhower Executive Office Building in DC yesterday. youtube.com/watch?v=kq8Hed…

Read an interview with OCE Director Richard Pazdur about causes of oncology drug shortages and what the FDA can and can't do to fix it, via The Cancer Letter open access article.

New article posted: "When Diversity Goals Meet Multiregional Trials" via NEJM by FDA authors @gautammehtamd Rick Pazdur Dr. Namandjé N. Bumpus and Dr. Robert M. Califf. nejm.org/doi/full/10.10… #OCEPublications